Published in Clin Pharmacol Ther on March 01, 1980
Spironolactone dose-response relationships in healthy subjects. Br J Clin Pharmacol (1982) 0.80
Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience. Br J Clin Pharmacol (1982) 0.75
Influence of spironolactone on neonatal screening for congenital adrenal hyperplasia. Arch Dis Child Fetal Neonatal Ed (1999) 0.75
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet (1995) 7.59
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 3.88
Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart (1999) 3.53
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet (1998) 3.41
Early deaths in Jamaican children with sickle cell disease. Br Med J (1978) 3.38
Local confidential inquiry into avoidable factors in deaths from stroke and hypertensive disease. BMJ (1993) 3.25
Effect of season and temperature on mortality in amphibians due to chytridiomycosis. Aust Vet J (2004) 3.16
Evidence for multiple structural genes for the gamma chain of human fetal hemoglobin. Proc Natl Acad Sci U S A (1968) 3.05
The rhythm of the normal human heart. Lancet (1976) 2.94
Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) (1996) 2.88
Domain-specific knowledge systems in the brain the animate-inanimate distinction. J Cogn Neurosci (1998) 2.79
Oxidation phenotype--a major determinant of metoprolol metabolism and response. N Engl J Med (1982) 2.72
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart (1999) 2.69
Investigation of selected patients with hypertension by the rapid-sequence intravenous urogram. Lancet (1992) 2.65
The Elag-Koln automatic blood pressure recorder. A clinical appraisal. Br Heart J (1977) 2.34
An examination of conditions for the cleavage of polypeptide chains with cyanogen bromide: application to catalase. Arch Biochem Biophys (1969) 2.23
Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. Br Med J (Clin Res Ed) (1982) 2.00
The present status of the heterogeneity of fetal hemoglobin in beta-thalassemia: an attempt to unify some observations in thalassemia and related conditions. Ann N Y Acad Sci (1974) 1.99
Clinical evaluation of Dinamap 845 automated blood pressure recorder. Br Heart J (1980) 1.94
Coordinating and standardizing long-term care: evaluation of the west of Scotland shared-care scheme for hypertension. Br J Gen Pract (1994) 1.92
Sample size for short-term trials of antihypertensive drugs. Br J Clin Pharmacol (1982) 1.91
Spatio-temporal stages in face and word processing. I. Depth-recorded potentials in the human occipital, temporal and parietal lobes [corrected]. J Physiol Paris (1994) 1.81
Bumetanide: potent new "loop" diuretic. Br Med J (1972) 1.74
Hazards of beta-blocker/diuretic tablets. Lancet (1985) 1.72
The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed) (1984) 1.71
Intracerebral potentials to rare target and distractor auditory and visual stimuli. I. Superior temporal plane and parietal lobe. Electroencephalogr Clin Neurophysiol (1995) 1.67
Weight reduction in a blood pressure clinic. Br Med J (1978) 1.67
Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients. Clin Pharmacol Ther (1980) 1.64
Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Clin Radiol (2002) 1.61
The complete amino acid sequence of bovine liver catalase and the partial sequence of bovine erythrocyte catalase. Arch Biochem Biophys (1982) 1.60
Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed) (1983) 1.58
Efficacy of anticoagulation in the U.K. Lancet (1981) 1.58
Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. Br J Clin Pharmacol (1982) 1.55
Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays? Br Med J (Clin Res Ed) (1983) 1.53
Patients' attitudes to participation in clinical trials. Br J Clin Pharmacol (1993) 1.52
Spatio-temporal stages in face and word processing. 2. Depth-recorded potentials in the human frontal and Rolandic cortices. J Physiol Paris (1994) 1.50
Intracerebral potentials to rare target and distractor auditory and visual stimuli. III. Frontal cortex. Electroencephalogr Clin Neurophysiol (1995) 1.50
Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens (1990) 1.50
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens (2001) 1.49
Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses. Br J Clin Pharmacol (1975) 1.48
Haemodynamic changes after angiocardiography. Br Heart J (1969) 1.46
Cell surface polypeptide CshA mediates binding of Streptococcus gordonii to other oral bacteria and to immobilized fibronectin. Infect Immun (1996) 1.45
Intracerebral potentials to rare target and distractor auditory and visual stimuli. II. Medial, lateral and posterior temporal lobe. Electroencephalogr Clin Neurophysiol (1995) 1.42
The partial amino acid sequence of human erythrocyte catalase. Arch Biochem Biophys (1982) 1.42
An improved method for quantitative determination of human fetal hemoglobin. Anal Biochem (1970) 1.41
Coronary atheroma regression trials. Lancet (1992) 1.40
The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet (1996) 1.40
Open access carotid duplex scanning: throughput and resultant surgical workload. Ann R Coll Surg Engl (2000) 1.39
Antihypertensive and adverse biochemical effects of bendrofluazide. BMJ (1990) 1.39
Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet (1986) 1.35
Liver dysfunction in hypertension. Lancet (1977) 1.35
The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Lond (1987) 1.35
Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis (1981) 1.33
Ketanserin in essential hypertension: a double-blind, placebo-controlled study. Postgrad Med J (1985) 1.32
Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens (1988) 1.31
Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide? Br Med J (Clin Res Ed) (1983) 1.31
Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. QJM (1999) 1.28
Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays? Br Med J (Clin Res Ed) (1983) 1.24
Quantification of side-effects of beta-adrenoceptor blockers using visual analogue scales. Br J Clin Pharmacol (1984) 1.24
The amino acid sequence of bovine liver catalase: a preliminary report. Arch Biochem Biophys (1969) 1.23
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther (1983) 1.22
Factors influencing serum potassium in treated hypertension. Q J Med (1977) 1.22
The dissociation of color from form and function knowledge. Nat Neurosci (2001) 1.20
Preparation and characterization of a pentaammineruthenium(III) derivative of horse heart ferricytochrome c. Proc Natl Acad Sci U S A (1982) 1.20
Presentation of thyroid carcinoma as a thrombosed external jugular vein, with intraluminal tumour thrombus in the great veins. Eur J Surg Oncol (2000) 1.20
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens (2001) 1.19
Selection and breeding of plant cultivars to minimize cadmium accumulation. Sci Total Environ (2007) 1.18
Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol (1983) 1.17
Evidence for multiple structural genes for the gamma-chain of human fetal hemoglobin in hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci (1969) 1.17
Impact of venography on the diagnosis and management of deep vein thrombosis. Br Med J (Clin Res Ed) (1983) 1.15
Policies for managing hypertensive patients: a survey of the opinions of British specialists. J Hum Hypertens (1990) 1.14
Oral sustained-release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations. Br J Clin Pharmacol (1980) 1.14
Assessment of myocardial function before aortic surgery by radionuclide angiocardiography. Br J Surg (1985) 1.12
Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol (1988) 1.12
Diuretic treatment of resistant hypertension. Br Med J (1980) 1.12
Rheumatoid nodule of pharynx. Br Med J (1977) 1.12
Preliminary evaluation of pinacidil in hypertension. Br J Clin Pharmacol (1983) 1.11
Identification of QTL and association of a phytoene synthase gene with endosperm colour in durum wheat. Theor Appl Genet (2006) 1.09
Intestinal function and intestinal blood supply: a 20 year surgical study. Gut (1985) 1.08
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Prevalence of persistent cough during long-term enalapril treatment: controlled study versus nifedipine. Q J Med (1991) 1.08
Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens (1999) 1.08
Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1985) 1.07
The association between haemospermia and severe hypertension. Postgrad Med J (1991) 1.07
Non-steroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: a report of two cases. Gut (1992) 1.06
Fatal pneumococcal meningitis in adults following splenectomy: two case reports and a review of the literature. J R Nav Med Serv (1973) 1.06
Safety of domperidone. Lancet (1982) 1.06
Mode of action of a surgical electronic lithoclast--high speed pressure, cinematographic and schlieren recordings following an ultrashort underwater electronic discharge. Biomed Eng (1976) 1.05
Relative potency of spironolactone, triamterene and potassium chloride in thiazide-induced hypokalaemia. Br J Clin Pharmacol (1982) 1.04
Results of the combined fundic patch-fundoplication operation in the treatment of reflux esophagitis with stricture. Surg Gynecol Obstet (1972) 1.04
Diuretic and beta-blocker in hypertension--then what? J R Coll Physicians Lond (1980) 1.03
Hydralazine once daily in hypertension. Br Med J (Clin Res Ed) (1982) 1.03
Hereditary persistence of fetal hemoglobin. Heterogeneity of fetal hemoglobin in homozygotes and in conjunction with -thalassemia. N Engl J Med (1971) 1.03
The sites of action of bumetanide in man. Eur J Pharmacol (1973) 1.02
Bumetanide and frusemide: a comparison of dose-response curves in healthy men. Br J Clin Pharmacol (1978) 1.02